Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by Vedanta Biosciences
Vedanta Biosciences Announces the Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. difficile Infection Will Continue as Planned Following Protocol-Specified Interim Analysis
April 02, 2026
From
Vedanta Biosciences
Via
Business Wire
Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint
August 13, 2025
From
Vedanta Biosciences
Via
Business Wire
Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine
January 23, 2025
From
Vedanta Biosciences
Via
Business Wire
Vedanta Biosciences To Present at IDWeek 2024 on Benefit of VE303 on Antibiotic Resistant Gene Levels in Patient Microbiomes
October 16, 2024
From
Vedanta Biosciences
Via
Business Wire
Vedanta Biosciences Expands Leadership Team and Appoints Head of Commercial
July 23, 2024
From
Vedanta Biosciences
Via
Business Wire
Vedanta Biosciences Enrolls First Patient in Pivotal Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. difficile Infection
May 21, 2024
From
Vedanta Biosciences
Via
Business Wire
Vedanta Biosciences to Present at Upcoming Investor Conferences
April 29, 2024
From
Vedanta Biosciences
Via
Business Wire
Vedanta Biosciences to Host Investor Meetings at the Leerink Partners 2024 Global Biopharma Conference
March 06, 2024
From
Vedanta Biosciences
Via
Business Wire
Vedanta Biosciences’ Key Microbiome Patents Fully Upheld in Three European Opposition Proceedings
November 28, 2023
From
Vedanta Biosciences
Via
Business Wire
Vedanta Biosciences to Host Investor Meetings at the Wells Fargo Virtual Private Biotech Symposium
October 25, 2023
From
Vedanta Biosciences
Via
Business Wire
Vedanta Biosciences Presents Progress from Two Defined Bacterial Consortia, VE303 for the Prevention of C. difficile and VE707 for the Prevention of Gram-Negative Infections, at IDWeek 2023
October 11, 2023
From
Vedanta Biosciences
Via
Business Wire
Vedanta Biosciences to Participate at Upcoming Investor Conferences
October 05, 2023
From
Vedanta Biosciences
Via
Business Wire
Vedanta Biosciences Announces First Patient Dosed in Phase 2 Clinical Trial of VE202 for the Treatment of Ulcerative Colitis and Receives Fast Track Designation
October 04, 2023
From
Vedanta Biosciences
Via
Business Wire
Vedanta Biosciences to Participate in the JMP Securities Life Sciences Conference
May 09, 2023
From
Vedanta Biosciences
Via
Business Wire
Vedanta Biosciences Receives Fast Track Designation for VE303 and Presents Phase 2 Data at Digestive Disease Week
May 08, 2023
From
Vedanta Biosciences
Via
Business Wire
Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies
April 25, 2023
From
Vedanta Biosciences
Via
Business Wire
Vedanta Biosciences Publishes Phase 2 Results in the Journal of the American Medical Association and Presents at ECCMID
April 17, 2023
From
Vedanta Biosciences
Via
Business Wire
Vedanta Biosciences to Present at Upcoming Investor Conferences
January 26, 2023
From
Vedanta Biosciences
Via
Business Wire
Vedanta Biosciences to Present at the 9th International Human Microbiome Consortium Congress
November 09, 2022
From
Vedanta Biosciences
Via
Business Wire
Vedanta Biosciences to Present at Upcoming Investor Conferences
July 07, 2022
From
Vedanta Biosciences
Via
Business Wire
Vedanta Unveils State-of-the-Art Manufacturing Facility to Provide Clinical and Commercial Supply of Oral Therapies Based on Defined Bacterial Consortia
June 28, 2022
From
Vedanta Biosciences
Via
Business Wire
Vedanta Biosciences to Participate in the JMP Securities Life Sciences Conference
June 08, 2022
From
Vedanta Biosciences
Via
Business Wire
Vedanta Presents Data from Multiple Studies at Digestive Disease Week 2022 Annual Meeting
May 24, 2022
From
Vedanta Biosciences
Via
Business Wire
Tickers
PRTC
Vedanta Biosciences Publishes Phase 1a/1b Results for Lead Program VE303 in Cell Host & Microbe and Highlights Planned Presentations of Phase 2 VE303 Results
April 13, 2022
From
Vedanta Biosciences
Via
Business Wire
Vedanta Biosciences to Present at Chardan’s 2022 Metagenomics and Microbiome Medicines Summit
February 23, 2022
From
Vedanta Biosciences
Via
Business Wire
Vedanta Biosciences Appoints Simona Levi as Chief Legal Officer and Corporate Secretary
October 14, 2021
From
Vedanta Biosciences
Via
Business Wire
Vedanta Biosciences Presents New Data from Phase 1 Study of VE202, Its Rationally-Defined Consortium for the Treatment of Inflammatory Bowel Disease, at the International Human Microbiome Consortium Congress 2021 (IHMC)
June 29, 2021
From
Vedanta Biosciences
Via
Business Wire
Tickers
PRTC
Vedanta Biosciences to Present at the SVB Leerink Biopharma Private Company Connect Event
April 29, 2021
From
Vedanta Biosciences
Via
Business Wire
Vedanta Biosciences to Present at the 2021 Jefferies Virtual Microbiome-Based Therapeutics Summit
April 15, 2021
From
Vedanta Biosciences
Via
Business Wire
Tickers
PRTC
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
